Helix pomatia agglutinin bound to surface glycans of small extracellular vesicles in-vitro and in-vivo increases in early and late stage breast cancer
Breast Cancer · 2025
DOI: 10.1007/s12282-025-01724-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer, 2025. Verfasst von Jamie Cooper und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological and Medical Sciences, Oxford Brookes University, Headington Campus, Oxford, OX3 0BP, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Extracellular Vesicles, Polysaccharides, Lectins. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Oxford Brookes University.
Abstract (Originalsprache)
Background
Breast cancer is the most frequently diagnosed cancer and a leading cause of cancer-related mortality in women globally. Small extracellular vesicles (sEVs) play a crucial role in cell communication and cancer progression. This study aimed to investigate the glycosylation patterns of sEVs derived from breast epithelial cells and plasma samples from breast cancer patients, focusing on the presence of truncated O-linked glycans, such as the Tn antigen, using Helix pomatia agglutinin (HPA).
Methods
Breast cancer cell lines were investigated for HPA lectin surface binding by confocal microscopy and flow cytometry. The sEVs of these were tested for surface HPA and tetraspanin binding using imaging-flow cytometry, single particle interferometry, and direct stochastical optical reconstruction microscopy. Plasma from healthy and stage II-IV breast cancer patients were tested by imaging-flow cytometry for HPA binding and analyzed for the source of HPA + EVs using 37 colocalised markers by multiplex flow cytometry .
Results
Quantitative analysis revealed elevated HPA binding in sEVs from metastatic MCF-7 cells compared to that in non-metastatic BT-474 and immortalized healthy normal hTERT-HME1 cells, suggesting a correlation between HPA binding and metastatic potential. Analysis of sEVs revealed differential glycan presentation with CD81-positive sEVs from MCF-7 cells compared to CD63. In patient-derived plasma sEVs, HPA binding was significantly higher in patients with breast cancer than in healthy individuals, highlighting its potential as a biomarker for cancer detection.
Conclusions
These findings highlight the complex glycosylation of sEVs and their potential early diagnostic utility in breast cancer for HPA positive sEVs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biological and Medical Sciences, Oxford Brookes University, Headington Campus, Oxford, OX3 0BP, UK.
- School of Biological and Medical Sciences, Oxford Brookes University, Headington Campus, Oxford, OX3 0BP, UK. rpink@brookes.ac.uk.
Förderung
- Oxford Brookes University
Zitieren
APA
Cooper, J., Airstone, B., Beaman, E., Carollo, E., Brooks, S. A., & Pink, R. C. (2025). Helix pomatia agglutinin bound to surface glycans of small extracellular vesicles in-vitro and in-vivo increases in early and late stage breast cancer. Breast Cancer. https://doi.org/10.1007/s12282-025-01724-4
Vancouver
Cooper J, Airstone B, Beaman E, Carollo E, Brooks SA, Pink RC. Helix pomatia agglutinin bound to surface glycans of small extracellular vesicles in-vitro and in-vivo increases in early and late stage breast cancer. Breast Cancer. 2025. doi:10.1007/s12282-025-01724-4
BibTeX
@article{Cooper2025,
author = {Cooper, Jamie and Airstone, Bethy and Beaman, Ellie and Carollo, Emanuela and Brooks, Susan Ann and Pink, Ryan Charles},
title = {Helix pomatia agglutinin bound to surface glycans of small extracellular vesicles in-vitro and in-vivo increases in early and late stage breast cancer},
journal = {Breast Cancer},
year = {2025},
doi = {10.1007/s12282-025-01724-4}
}
EUVIMED